An influential panel in the US House of Representatives on Thursday urged sweeping restrictions on outbound investment in Chinese biotechnology, as it pushed for the advancement of a bill to restrict the industry’s operations in the American market.
The hearing held by the House select committee on competition with China came after a Senate committee voted 11-1 on Wednesday backing a companion bill prohibiting US federally-funded institutions from contracting with certain biotech providers in China.
